Some women with ovarian, fallopian tube, or primary peritoneal cancer have cancer cells remaining after treatment with chemotherapy. In this study, researchers are evaluating the safety and effectiveness of the drug ipilimumab in these patients. Ipilimumab is approved for treating advanced melanoma, but its use in this study is considered investigational.
Ipilimumab is an antibody against CTLA-4, a molecule that controls a part of the immune system by shutting it down. Researchers believe that one way cancers can escape the immune system could be through this shut-down mechanism. An antibody against CTLA-4 could stop it from turning off the immune system, and allow an immune reaction to continue. This immune reaction may help the body to destroy remaining cancer cells.